Medtronic and Abbott are often seen as rivals in a competitive marketplace, but the two companies are collaborating with a simple goal in mind: improving patient access to high-quality CGM devices. 

The new medical device correction only includes a select number of devices. Abbott said they produce inaccurate readings, putting patient health at risk. 

The diabetes drug, sold by Eli Lilly and Company under the brand names Zepbound and Mounjaro, was associated with better outcomes, improved symptoms and more significant weight loss than a placebo.

A team of Cleveland Clinic specialists tracked data from more than 13,000 patients, focusing on all-cause mortality and long-term cardiovascular outcomes.

The new PREVENT CVD risk calculator could result in more than 16 million heart patients who are no longer eligible for preventive therapy. These significant changes “carry the potential for both benefit and harm," researchers wrote in JAMA.

Compounded semaglutide injectable products are at the heart of these concerns. While the FDA says compounded drugs “can serve an important medical need for patients,” the agency does not approve these new formulations, increasing the risk of complications. 

Abandoned metal wire leads for pacemakers and ICDs did not present a serious safety issue in a study of 80 patients, but a handful of patients did experience a significant change in the composite of capture threshold, sensing or lead impedance.

U.S. News and World Report reviewed 660 hospitals, ranking them based on data related to treating diabetes and endocrinology.